

P0311 **The first Russian case of candidaemia due to *Candida auris***

Natalya Vasilyeva*¹, Alexander Kruglov², Ivan Mikhailovich Pchelín¹, Igor Riabinin¹, Ekaterina Raush¹, Galina Chilina¹, Tatiyana Bogomolova¹, Ilya Bosak¹, Olga Shurpitskaya¹, Nikolai Klimko³, Olesya Generalova⁵, Nikolay Kruglyakov⁴, Anastasiya Taraskina¹

¹NWSMU n.a. I.I.Mechnikov, Kashkin Research Institute of Medical Mycology, Saint-Petersburg, Russian Federation, ²National Agency of Clinical Pharmacology and Pharmacy, Laboratory of microbiology, Moscow, Russian Federation, ³NWSMU n.a. I.I.Mechnikov, Chair of clinical mycology, allergology and immunology, Saint-Petersburg, Russian Federation, ⁴A.I. Burnazyan Federal Medical-Biophysical Centre, Federal Medical-Biological Agency of Russia, Moscow, Russian Federation, ⁵National Agency of Clinical Pharmacology and Pharmacy, Laboratory of Microbiology, Moscow, Russian Federation

Background: *Candida auris* is an emerging multidrug-resistant species, which is associated with invasive infection and high rates of mortality. Originally it was isolated in 2008 in Japan. Since then, *C. auris* infections have been reported from South Korea, India, Pakistan, Kuwait, Israel, South Africa, and the United Kingdom and, more recently, in Venezuela, Colombia, United States and the Continental Europe (Spain).

We report on the clinical and microbiology characteristics of first candidaemia episode by *C. auris* obtained in the intensive care unit (ICU) of hospital in Moscow, Russia.

Materials/methods: *C. auris* isolate RCPFY-1821 was obtained from blood culture of ICU patient suffering an acute stroke. Identification was done by MALDI-TOF-MS. We performed DNA sequencing of the locus *TEF1α* with AL33 primers and confirmed the identification of the strain by blast search against *C. auris* whole-genome shotgun contigs. Antifungal susceptibility testing of *C. auris* isolate for azoles, amphotericin B and caspofungin was determined by microbroth dilution method (CLSI M27-A3).

Results: The patient's age was 88 years (female). The risk factors for the development of candidaemia were immunosuppression, AVL and administration of broad spectrum antibiotics. The patient was treated with anidulafungin for six weeks. She had a fatal outcome in spite of antifungal therapy. *C. auris* isolate grew well at 37 °C on Sabouraud dextrose agar developing smooth matte creamy colonies with even edges after 72 hours incubation. The microscopical examination revealed oval, colorless, budding cells (2.0-2.8 x 3.4-4.1 μM). Hyphae and pseudohyphae were absent. Obtained *TEF1α* sequence was 601 b.p. and was identical to sequences from isolates B8441 (Pakistan) and 6684 (India). Sequences from other countries were not available for comparison. The mass-spectrum obtained had the greatest similarity with main spectral profile «*C. auris* DSM 21092T CBS». The maximum score value was 1.898. The strain was resistant to FLU (MIC 128 μg/ml), VRC (MIC 8 μg/ml), POS (MIC 2 μg/ml), CAS (MIC 4 μg/ml), and susceptible to AMB (MIC 0,5 μg/ml).

Conclusions: The present study reports the first candidaemia episode by *C. auris* in Russia. The emergence of *C. auris* requires the implementation of infection control measures to prevent isolates dissemination.